ABY 035

Drug Profile

ABY 035

Alternative Names: ABY035; AFB-035

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affibody
  • Class Anti-inflammatories; Antipsoriatics
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis
  • Phase I/II Psoriasis
  • Preclinical Inflammation

Most Recent Events

  • 14 Nov 2017 Phase-II clinical trials in Plaque psoriasis in Germany (SC) (EudraCT2017-001615-36)
  • 01 Nov 2017 Federal Institute for Drugs and Medical Devices (BfArM) approves clinical trial application for initiation of a phase II trial in Plaque psoriasis in Germany
  • 01 Aug 2017 Affibody files a CTA application with Federal Institute for Drugs and Medical Devices (BfArM) for initiation of a phase II trial in Plaque psoriasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top